Zacks Investment Research Downgrades Insmed (INSM) to Hold


According to Zacks, "Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung infections and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company's inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension , a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.



from Biotech News